Critical Review: Nyxoah (NASDAQ:NYXH) versus Carmell (NASDAQ:CTCX)

Nyxoah (NASDAQ:NYXH) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nyxoah and Carmell, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	4	0	3.00
Carmell	0	0	0	0	0.00

Nyxoah presently has a consensus price target of $15.25, suggesting a potential upside of 38.01%. Given Nyxoah’s stronger consensus rating and higher possible upside, equities analysts plainly believe Nyxoah is more favorable than Carmell.

Earnings and Valuation

This table compares Nyxoah and Carmell”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.52 million	83.25	-$46.77 million	($1.95)	-5.67
Carmell	$32,839.00	141.83	-$15.44 million	N/A	N/A

Carmell has lower revenue, but higher earnings than Nyxoah.

Insider & Institutional Ownership

24.2% of Carmell shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 29.0% of Carmell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Nyxoah has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Nyxoah and Carmell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
Carmell	N/A	-217.50%	-50.22%

Summary

Nyxoah beats Carmell on 7 of the 12 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.